Split History
ETFs Holding TTPH »    TTPH Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Tetraphase Pharmaceuticals is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant (MDR), bacteria. Co. developes its product, XeravaTM (eravacycline), a fully synthetic fluorocycline, as an intravenous, antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections. In addition to Xerava, Co. is also developing other fluorocycline antibiotic compounds, TP-6076 and TP-271, and TP-2846. According to our TTPH split history records, Tetraphase Pharmaceuticals has had 1 split.
TTPH split history picture
Tetraphase Pharmaceuticals (TTPH) has 1 split in our TTPH split history database. The split for TTPH took place on September 27, 2019. This was a 1 for 20 reverse split, meaning for each 20 shares of TTPH owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.

When a company such as Tetraphase Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the TTPH split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Tetraphase Pharmaceuticals shares, starting with a $10,000 purchase of TTPH, presented on a split-history-adjusted basis factoring in the complete TTPH split history. TTPH split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 03/20/2013
End date: 12/06/2019
Start price/share: $140.00
End price/share: $2.23
Dividends collected/share: $0.00
Total return: -98.41%
Average Annual Total Return: -46.00%
Starting investment: $10,000.00
Ending investment: $159.32
Years: 6.72
Date Ratio
09/27/20191 for 20
TTPH is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

UHS Split History
UNIS Split History
USPH Split History
UTHR Split History
VAR Split History
VBIV Split History
VICL Split History
VIV Split History
VIVO Split History
VLRX Split History

Also explore: TTPH shares outstanding history

iMedia Brands, Inc. (IMBI)
Akers Biosciences, Inc. (AKER)
NeuroMetrix, Inc. (NURO)
TRACON Pharmaceuticals (TCON)
SELLAS Life Sciences Group, Inc. (SLS)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Camber Energy, Inc. (CEI)
Cancer Genetics, Inc. (CGIX)
Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3X Shares (GUSH)
Kingold Jewelry, Inc. (KGJI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

TTPH Insider Buying

TTPH Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.